午夜A片麻豆精东传媒_国产午夜精品一区二区三区四区_八戒午夜福利理论片_午夜福利电影_午夜成人性做爰A片无码潘金莲_午夜家庭影院_久久午夜无码鲁丝片午夜精品_午夜福利三级理论电影_国产午夜精品一区二区_潘金莲裸体午夜理伦A片_婷婷涩嫩草鲁丝久久午夜精品_午夜视频

這(zhè)是(shì)描述信息
Search
Submit
Cancel
Nanjing RegeneCore Biotech Co.,Ltd
Nanjing RegeneCore Biotech Co.,Ltd

REGENECORE is an innovative start-up comp€♠εany under the YOUNGY Gro™>φ∑up, advocating science and α≥>culture, paying atteγ♥βntion to the growth of empl↓$‍₹oyees and enterprises, and maintaining human heal¶ε∏δth.

Nanjing RegeneCore Biotech Co.,Ltd
Nanjing RegeneCore Biotech Co.,∞ Ltd

Mature and complete nanobody humanization technol§β‌♥ogy platform, antibodyφβ↓ immunogenicity detec​≠tion technology platform, and high-th↑≠εδroughput nanobody screening techn"♦≈↔ology platform.

這(zhè)是(shì)描述信息

Nanjing RegeneCore Biotech Co.,Ltd

Nanjing RegeneCore Biotech Co.,Ltd is esta↕☆&blished in the Biomedical Va≥φlley of National Nanjing Jiangbei∞γ New Area, with a research and o αffice base of nearly 4000 square meters.±< It is one of the first research and'γπ$ development institutio•♦←≈ns in the field of nanobodies in China.>✘δ The company's international scientifi≠ c consulting expert team has rich expe☆±δrience in the research and ≥♣"♥development of cell the ≈rapy products and clinical application ♦s, providing strong guara↔×≤>ntees for the precise positioning and success ra $♣>te of research and development products. The cπ☆≠§ompany has mature and leading"₹ nanobody screening♠↑ technology, and conducts in-de€∞‍pth development in multiple applicat ‌₹ion fields based on this technology.

more
company

NEWS

Nanjing Rongjiekang RC1416 dual antibody has obtained 2 clinical trial licenses again

Nanjing Rongjiekang RC1₹​416 dual antibody ha✘§☆s obtained 2 clinical trial licenses again

Recently, Nanjing RegeneCore Biotechnolo≤✘↓gy Co., Ltd.'s RC1416 project↓>₩ has consecutively obtained Investigat↓₽♦ional New Drug (IND) approvals fro★ αφm the National Medical Products Administration's★≥ Center for Drug Evaluation'≤ (CDE) for indications of atopic dermatitis ‌‌≈α(AD) and chronic obstructive pulmo≤δ≠nary disease (COPD). The expansion of these•←₽× indications has further diversifi‍∞β♥ed the clinical application scenarios of RC141♠γ6 injection, providing bet¥₽®ter treatment options for more pat αients..
融捷集團:競逐新賽道(dào),勇攀生(shēng)命科(kē)技(jì)高(gāo)峰

融捷集團:競逐新賽道(dào),勇攀生(shēn≠♦ ¶g)命科(kē)技(jì)高(gāo)峰

近(jìn)日(rì),南京博爾迪生物科技有限公司發布的(de)一(yī)則招募中重度哮喘患者δ→≈'的(de)消息引人(rén)關注。原來(lái),由融捷康自(zì)研的(de)國(λ♥guó)內(nèi)首個(gè)自(zì)免₩'∞♣雙特異性納米抗體(tǐ)藥物(wù)——RC1416注射¶€₹$液,正在全國(guó)數(shù)十家(jiā)知(zhī)名醫(yī)院開(kāi✘©©¥)展臨床研究。這(zhè)款雙抗藥品在藥效、安全性和(∞≈σ™hé)成藥性等多(duō)重指标上(shàng)具有(y♦←©‍ǒu)較好(hǎo)的(de)優勢,未來(lái)有(yǒu)望成為(wèi)中ᶧ&重度哮喘患者的(de)福音(yīn)。
Recruitment of Patients with Moderate to Severe Asthma

Recruitment of Patients with Moderate ®"σ to Severe Asthma

RC1416 injection, developed by Nanjingλβ RegeneCore Biotech Co.,Ltd, is ₩&♦±currently undergoing a Phase Ib clini​λ∑♥cal study to "evaluate the safety, tole✘↓≥←rability, pharmacokinetics, pharmacody✘•πδnamics, immunogenicity, and prelimi±×&nary effectiveness of RC1416 injection in ε ✘↕patients with moderate to seφαvere asthma." The lead institution for th§↓≈is study is the Chin∑$¶¶a-Japan Friendship Hospital in Beijing, and i←♦t is simultaneously being conducted at dozen•↑s of renowned hospitals across the ♦§✔country.

 

Platforms

High throughput nanobo£α✘dy screening technology platform, nanobodδ≤y humanization technologβ&®‌y platform, antibody immunogenicity detection↔• " technology platform, biomacromol↑€ecule analysis technology pl₽‍™₩atform, antibody drug CMC λ process development technology platf¶®ββorm

TEL:

025-58608860

Address: Room 07 ≤∏✔←;Building 16 Treehouse, N₩' ♥o. 73, Tanmi Road, Jian★Ω•'gbei New District, Nanjing

Enterprise email:rjk@regenecore.com

 

這(zhè)是(shì)描述信息

WeChat cooperative consultation

You are the th visitor

午夜A片麻豆精东传媒_国产午夜精品一区二区三区四区_八戒午夜福利理论片_午夜福利电影_午夜成人性做爰A片无码潘金莲_午夜家庭影院_久久午夜无码鲁丝片午夜精品_午夜福利三级理论电影_国产午夜精品一区二区_潘金莲裸体午夜理伦A片_婷婷涩嫩草鲁丝久久午夜精品_午夜视频